Lynx Biosciences

We are an interdisciplinary, science-driven, and multicultural team supported by a world-class advisory board and visionary investors, all dedicated to propelling the frontier of immuno-oncology and immunology therapies. LynxBio is at the forefront of a data-first paradigm shift in drug discovery, leveraging our proprietary patient-based ex vivo disease biology platform. LynxBio collaborates with leading biopharma and technology companies to explore diverse disease domains and rapidly identify novel, best-in-class therapeutic candidates, with an initial focus on immuno-oncology. Lynx Biosciences Appoints Sylvaine Cases, Ph.D., as Chief Business Officer. Our platform is engineered to decode the intricacies of this complexity, delivering transformative, data-centric (versus hypothesis-driven) insights that blend biotechnology with technology and accelerate the development of groundbreaking therapies from discovery to bedside. To date, we have formed several strategic partnerships with leading biopharmaceutical companies, underscoring the industry's recognition of our platform's potential. In tandem with these alliances, we are advancing an internal pipeline centered on novel signaling pathways that orchestrate the interplay between immune cells, cancer cells, and the tumor microenvironment.